163 related articles for article (PubMed ID: 30569861)
1. Arginine Deiminase: Current Understanding and Applications.
Zarei M; Rahbar MR; Morowvat MH; Nezafat N; Negahdaripour M; Berenjian A; Ghasemi Y
Recent Pat Biotechnol; 2019; 13(2):124-136. PubMed ID: 30569861
[TBL] [Abstract][Full Text] [Related]
2. Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug.
Han RZ; Xu GC; Dong JJ; Ni Y
Appl Microbiol Biotechnol; 2016 Jun; 100(11):4747-60. PubMed ID: 27087524
[TBL] [Abstract][Full Text] [Related]
3. Rapid evolution of arginine deiminase for improved anti-tumor activity.
Ni Y; Liu Y; Schwaneberg U; Zhu L; Li N; Li L; Sun Z
Appl Microbiol Biotechnol; 2011 Apr; 90(1):193-201. PubMed ID: 21221572
[TBL] [Abstract][Full Text] [Related]
4. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.
Synakiewicz A; Stachowicz-Stencel T; Adamkiewicz-Drozynska E
Expert Opin Investig Drugs; 2014 Nov; 23(11):1517-29. PubMed ID: 24965808
[TBL] [Abstract][Full Text] [Related]
5. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.
Wang M; Basu A; Palm T; Hua J; Youngster S; Hwang L; Liu HC; Li X; Peng P; Zhang Y; Zhao H; Zhang Z; Longley C; Mehlig M; Borowski V; Sai P; Viswanathan M; Jang E; Petti G; Liu S; Yang K; Filpula D
Bioconjug Chem; 2006; 17(6):1447-59. PubMed ID: 17105223
[TBL] [Abstract][Full Text] [Related]
6. Arginine Deiminase Enzyme Evolving as a Potential Antitumor Agent.
Somani RR; Chaskar PK
Mini Rev Med Chem; 2018; 18(4):363-368. PubMed ID: 27538511
[TBL] [Abstract][Full Text] [Related]
7. Arginine deiminase, a potential anti-tumor drug.
Ni Y; Schwaneberg U; Sun ZH
Cancer Lett; 2008 Mar; 261(1):1-11. PubMed ID: 18179862
[TBL] [Abstract][Full Text] [Related]
8. Arginine-Depleting Enzymes - An Increasingly Recognized Treatment Strategy for Therapy-Refractory Malignancies.
Riess C; Shokraie F; Classen CF; Kreikemeyer B; Fiedler T; Junghanss C; Maletzki C
Cell Physiol Biochem; 2018; 51(2):854-870. PubMed ID: 30466103
[TBL] [Abstract][Full Text] [Related]
9. Amino Acids Sequence-based Analysis of Arginine Deiminase from Different Prokaryotic Organisms: An In Silico Approach.
Abdollahi S; Morowvat MH; Savardashtaki A; Irajie C; Najafipour S; Zarei M; Ghasemi Y
Recent Pat Biotechnol; 2020; 14(3):235-246. PubMed ID: 32208128
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of anti-tumor activity in melanoma using arginine deiminase fused with 30Kc19α protein.
Lee H; Park G; Kim S; Son B; Joo J; Park HH; Park TH
Appl Microbiol Biotechnol; 2022 Nov; 106(22):7531-7545. PubMed ID: 36227339
[TBL] [Abstract][Full Text] [Related]
11. Expression of arginine deiminase from Pseudomonas plecoglossicida CGMCC2039 in Escherichia coli and its anti-tumor activity.
Ni Y; Li Z; Sun Z; Zheng P; Liu Y; Zhu L; Schwaneberg U
Curr Microbiol; 2009 Jun; 58(6):593-8. PubMed ID: 19280262
[TBL] [Abstract][Full Text] [Related]
12. Rational surface engineering of an arginine deiminase (an antitumor enzyme) for increased PEGylation efficiency.
Cheng F; Yang J; Schwaneberg U; Zhu L
Biotechnol Bioeng; 2019 Sep; 116(9):2156-2166. PubMed ID: 31062871
[TBL] [Abstract][Full Text] [Related]
13. Characterization of mycoplasma arginine deiminase expressed in E. coli and its inhibitory regulation of nitric oxide synthesis.
Noh EJ; Kang SW; Shin YJ; Kim DC; Park IS; Kim MY; Chun BG; Min BH
Mol Cells; 2002 Feb; 13(1):137-43. PubMed ID: 11911465
[TBL] [Abstract][Full Text] [Related]
14. Evaluating Five Escherichia coli Derivative Strains as a Platform for Arginine Deiminase Overproduction.
Abdollahi S; Morowvat MH; Savardashtaki A; Irajie C; Najafipour S; Ghasemi Y
Recent Pat Biotechnol; 2022; 16(2):174-183. PubMed ID: 34809551
[TBL] [Abstract][Full Text] [Related]
15. PEGylation and pharmacological characterization of a potential anti-tumor drug, an engineered arginine deiminase originated from Pseudomonas plecoglossicida.
Zhang L; Liu M; Jamil S; Han R; Xu G; Ni Y
Cancer Lett; 2015 Feb; 357(1):346-354. PubMed ID: 25462857
[TBL] [Abstract][Full Text] [Related]
16. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
Kuo MT; Savaraj N; Feun LG
Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
[TBL] [Abstract][Full Text] [Related]
17. Arginine-lowering enzymes against cancer: a technocommercial analysis through patent landscape.
Dhankhar R; Gulati P; Kumar S; Kapoor RK
Expert Opin Ther Pat; 2018 Aug; 28(8):603-614. PubMed ID: 30092168
[TBL] [Abstract][Full Text] [Related]
18. In silico Analysis of Different Signal Peptides for Secretory Production of Arginine Deiminase in Escherichia coli.
Zarei M; Nezafat N; Morowvat MH; Ektefaie M; Ghasemi Y
Recent Pat Biotechnol; 2019; 13(3):217-227. PubMed ID: 30621572
[TBL] [Abstract][Full Text] [Related]
19. Medium Optimization for Recombinant Soluble Arginine Deiminase Expression in Escherichia coli Using Response Surface Methodology.
Zarei M; Nezafat N; Morowvat MH; Dehshahri A; Ghoshoon MB; Berenjian A; Ghasemi Y
Curr Pharm Biotechnol; 2017; 18(11):935-941. PubMed ID: 29336257
[TBL] [Abstract][Full Text] [Related]
20. Aspergillus nidulans thermostable arginine deiminase-Dextran conjugates with enhanced molecular stability, proteolytic resistance, pharmacokinetic properties and anticancer activity.
El-Sayed ASA; Shindia AA; Zeid AAA; Yassin AM; Sitohy MZ; Sitohy B
Enzyme Microb Technol; 2019 Dec; 131():109432. PubMed ID: 31615671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
